A combined synergistic effect of mixed tocotrienols (EVNol), curcumin, omega-3s, astaxanthin and other nutrients (Freedom Softgels formulated by Tischon Corp, USA) was found to significantly reduce inflammatory markers and systolic blood pressure in healthy subjects, based on a study published in Clinical Nutrition ESPEN.

This randomized, double-blinded, placebo-controlled, clinical trial was conducted at the Los Angeles Biomedical Research Institute at Harbor- UCLA Medical Center. A total of 80 healthy volunteers with mean age of 48.8 ± 16.0 years were enrolled and randomized to receive Freedom Softgels or placebo and followed for 4 weeks. The Freedom Softgels are produced by Tishcon, Westbury, NY and consist of 500 mg cavacurcumin (Wacker), 675 mg omega 3 (450 mg EPA + 100 mg DHA + other omega 3s 125 mg), 3 mg astaxanthin, 9.5 mg GLA, 12.5 mg mixed-tocotrienols (EVNol®), 6.25 mg hydroxy tyrosol, vitamin D3- 1000IU, and 12.75 mg potassium.  All participants were advised to take 2 softgels twice daily for 4 weeks.

After 4 weeks of supplementation, the study demonstrated a significant reduction of systolic blood pressure in individuals who received Freedom Softgels compared with the placebo. A normal systolic blood pressure is less than 120mmHg, which is an important factor to maintaining a healthy cardiovascular system. Inadequate control of systolic blood pressure rates is related to a variety of adverse cardiovascular outcomes.

In addition, the study demonstrated improvement in endothelial function in the group receiving Freedom Softgels, measured by brachial flow-mediated dilatation (bFMD). This measurement reflects changes in the brachial artery diameter after regional ischemia. The group receiving Freedom Softgels also showed a significant decrease of inflammatory biomarkers IL-6 and hsCRP. 

In healthy individuals, high levels of circulatory IL-6 are linked to increased risk of development and progression of ischemic heart disease. CRP, IL6 and its biomarkers have diagnostic and prognostic values in cardiovascular disease (CVD). Endothelial dysfunction is characterized by reduced vasodilation, a proinflammatory state, and prothrombic properties, which increases the risk of CVD, such as hypertension, coronary artery disease, chronic heart failure, peripheral artery disease, diabetes, and chronic renal failure. This finding suggests that Freedom Softgels could help in reducing inflammation and improving endothelial reactivity over a 4-week period.

SEE ALSO  5 surprising facts about fats that could make you healthier

The researchers concluded that reduction in systolic blood pressure and improvement of endothelial function with Freedom Softgels were likely due to its potent synergistic antioxidant and anti-inflammatory properties and that it has the potential to be used to complement antihypertensive therapies.

“Tocotrienol (EVNol) possesses diverse unique biological activities like antioxidant, anti-inflammatory and anti-aging properties. This synergistic combination of antioxidants and cardio-protective ingredients like curcumin, EPA, astaxanthin, tocotrienol (EVNol) and other nutrients, helps promote healthy cardiovascular function and other health benefits (such as better immune response) via its superior antioxidant and anti-inflammatory functions,” says Bryan See, Business Development Manager of ExcelVite.

“Dietary supplements have received considerable interest due to potential nutritional, safety and therapeutic effects. This trial validates that Freedom softgels containing cavacurcumin, omega 3, astaxanthin, GLA, with vitamin D, EVNol and hydroxytyrosol exhibits anti-inflammatory and antioxidant properties. Such observations highlight the importance and growing need for accessible and effective anti-inflammatory and anti-hypertensive interventions.” says Dr. Raj Chopra, CEO of Tishcon.


Birudaraju, D., Cherukuri, L., Kinninger, A., Chaganti, B. T., Shaikh, K., Hamal, S., … & Budoff, M. J. (2020). A combined effect of Cavacurcumin, Eicosapentaenoic acid (Omega-3s), Astaxanthin and Gamma–linoleic acid (Omega-6)(CEAG) in healthy volunteers-a randomized, double-blind, placebo-controlled study. Clinical Nutrition ESPEN, 35, 174-179.

Share This